2019
DOI: 10.23937/2572-3235.1510044
|View full text |Cite
|
Sign up to set email alerts
|

DIBH-VMAT for Consolidation RT in Mediastinal B-NHL can Significantly Reduce Doses to OAR Report of Two Cases

Abstract: has shown to improve significantly both overall survival (OS) and progression-free survival (PFS) even in the rituximab era significantly and also in patients with nonbulky-disease [1-3]. The advances with chemotherapy and radiotherapy have considerably increased the survival rates. Most of the patients are in a middle age of 50 to 60 years and the treatment is in principle curative with a five year PFS of 75-90%. Therefore on the one hand, DLBCL has to be adequately treated to reach a curative outcome, on the… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 24 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?